95 related articles for article (PubMed ID: 25337648)
1. Current and future intratumoral targeted treatment for pancreatic cancer.
Zarogoulidis P; Pavlioglou P; Pivert PL; Machairiotis N; Katsikogiannis N; Kougioumtzi I; Tsimogiannis K; Kakolyris S; Courcoutsakis N; Tsiouda T; Sakkas A; Makrantonaki D; Zarogoulidis K
Ther Deliv; 2014 Aug; 5(8):913-26. PubMed ID: 25337648
[TBL] [Abstract][Full Text] [Related]
2. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
3. NF-κB as a target for pancreatic cancer therapy.
Carbone C; Melisi D
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S1-10. PubMed ID: 22443181
[TBL] [Abstract][Full Text] [Related]
4. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
5. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
[TBL] [Abstract][Full Text] [Related]
7. Advanced or metastatic pancreatic cancer: molecular targeted therapies.
Bayraktar S; Rocha-Lima CM
Mt Sinai J Med; 2010; 77(6):606-19. PubMed ID: 21105124
[TBL] [Abstract][Full Text] [Related]
8. Aberrant signaling pathways in pancreatic cancer: a two compartment view.
McCleary-Wheeler AL; McWilliams R; Fernandez-Zapico ME
Mol Carcinog; 2012 Jan; 51(1):25-39. PubMed ID: 22162229
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
10. [Genetic aspects of pancreatic cancer].
Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
[TBL] [Abstract][Full Text] [Related]
11. Autophagy, p53, and pancreatic cancer.
Iacobuzio-Donahue CA; Herman JM
N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896
[No Abstract] [Full Text] [Related]
12. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
13. Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Chang DT; Chapman CH; Norton JA; Visser B; Fisher GA; Kunz P; Ford JM; Koong AC; Pai RK
Cancer; 2010 Nov; 116(22):5179-87. PubMed ID: 20665497
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
15. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
16. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
17. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Cottini F; Lautenschlaeger T
Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
[TBL] [Abstract][Full Text] [Related]
18. Novel therapies for pancreatic cancer.
Wolff RA
Cancer J; 2001; 7(4):349-58. PubMed ID: 11561610
[TBL] [Abstract][Full Text] [Related]
19. EGFR-targeted therapy.
Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
[TBL] [Abstract][Full Text] [Related]
20. [Palliative chemotherapy for colorectal cancer--current state, significance, trends].
Stübs P; Habermann P; Wex C; Mohren M; Zierau K; Lippert H; Fahlke J
Zentralbl Chir; 2010 Dec; 135(6):535-40. PubMed ID: 21154211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
